Fragrance or foolery: 15 big drug events will resolve before April
This article was originally published in Scrip
There are 15 big drug development decisions to be taken before April 1, seven of those in the hands of regulatory agencies in the US and Europe. The rest are dependent on clinical data, and some of the companies involved almost certainly already know which way the results going. All of which leaves 14 companies' senior management teams (Sanofi's has two clinical trials to ponder) wondering whether they will feel like bunches of April flowers, or bunches of fools.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.